维普期刊资源整合服务平台（V6.5）

32篇 您的检索式：作者名="Langabeer"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Incidence of CALR mutations in patients with splanchnic vein thrombosis 显示文摘	Haslam K Langabeer SE	2015	BrJHaematol2015，168，3：	1
2	Exploring the CI value equation 显示文摘	Langabeer J R	1999	Competitive Intelligence Review1999，，3：	1
3	Assessing the evidence of Six Sigma and Lean in the health care industry 显示文摘	Dellifraine JL Langabeer JR Nembhard IM	2010	Qual Manag Health Care2010，19，3：	1
4	Identification of the t(15;17) in AML FAB types other than M3:evaluation of the role of molecular screening for the PML/RARalpha rearrange ment in newly diagnosed AML显示文摘	Allford S Grimwade D Langabeer S	1999	Br J Haematol1999，105，1：	1
5	The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo- SCT显示文摘	Langabeer SE McCarron SL Haslam K	2014	Bone Marrow Transplant2014，49，6：	1
6	Prevalence of the JAK2V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis显示文摘	McCarthy N McCarron SL Langabeer SE	2010	Acta Haematol2010，124，：	1
7	Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: The role of molecular monitoring 显示文摘	Langabeer SE McCarron SL Kelly J	2012	Case Rep Hematol2012，2012，45：	1
8	Assessing the evidence of Six Sigma and Lean in the health care industry 显示文摘	DelliFraine J L Langabeer J R Nembhard I M	2010	Quality Management in Healthcare2010，19，3：	1
9	Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia显示文摘	Chelvatheebam S Langabeer S Linch DC	2003	Leuk Res2003，27，9：	1
10	Acute lymphoblastic leukaemia with an ela3 BCR-ABL1 fusion 显示文摘	Langabeer SE Haslam K Kelly J	2011	Acta Haematol2011，126，4：	1
11	Exploring the CI value equation显示文摘	Langabeer J R	1999	Competitive Intelligence Review1999，10，3：	1
12	Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:implications for the role of FLT3 mutations in leukemogenesis,minimal residual disease detection,and possible therapy with FLT3 inhibitors显示文摘	Kottaridis PD Gale RE Langabeer SE	2002	Blood2002，100，7：	1
13	Evil ex- pression in acute myeloid 显示文摘	Langabeer SE Rogers JR Harrison G	2001	Br J Haematol2001，112，：	1
14	Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors 显示文摘	Kottaridis PD Gale RE Langabeer SE	2002	Blood2002，100，7：	1
15	Glutathione s-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukemia显示文摘	Basu T Gale RE Langabeer S	1997	Lancet1997，349，：	1
16	Data envelop- ment analysis: performance normalization and benchmark- ing in heahhcare 显示文摘	Galterio L Helton J Langabeer JN	2009	J Health Inf Manag2009，23，3：	1
17	Minimal residual disease detection in acute promyelocytic leukemia by reverse transcriptase PCR: evaluation of PML RAR alpha and RAR alpha PML assessment in patients who ultimately relapse显示文摘	Grimwade D Howe K Langabeer S	1996	Leukemia1996，10，：	1
18	Identification of the t(15;17) in AML FAB types other than M3: evaluation of role of molecular screening for the PML/BAR-alpha rearrangement in newly diagnosed AML 显示文摘	Allford S Grimwade D Langabeer S	1999	Br J Haematol1999，105，1：	1
19	A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RARa, AML1/ETO and CBFB/MYHll respectively in acute myeloid leukemia显示文摘	Langabeer S E Grimwade D Walker H	1998	Br J Haematol1998，101，：	1
20	Incidence of CALR mutations in patients with splanchnic vein thrombosis 显示文摘	Haslam K Langabeer SE	2015	BrJHaematol2015，168，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示